JOSE ROBERTO FILASSI
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
11 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 11
- Patterns of post-operative radiotherapy in breast cancer patients after neoadjuvant chemotherapy(2017) LOPES, K. M.; FREITAS, T. B. De; CARVALHO, H. A.; PEREIRA, A. A.; SILVA, S. B.; STUART, S. R.; MANO, M. S.; FILASSI, J. R.; MARTA, G. N.
- Lymphocyte-predominant triple-negative breast carcinomas in premenopausal patients: Lower expression of basal immunohistochemical markers(2017) MASILI-OKU, Sergio Mitsuo; ALMEIDA, Bernardo Gomes Lacerda de; BACCHI, Carlos Eduardo; FILASSI, Jose Roberto; BARACAT, Edmund Chada; CARVALHO, Filomena MarinoObjectives: Triple-negative breast carcinomas (TNBCs) correspond to a molecular heterogeneous disease defined by lack of estrogen and progesterone receptor expression, and the absence of overexpression and/or amplification of HER2. Recent data indicate that clinical outcome in TNBC is affected by tumorinfiltrating lymphocytes, suggesting that they can benefit from immunotherapies. We selected 116 consecutive premenopausal patients with TNBC to compare the immunohistochemical profile of the group rich in tumor-infiltrating lymphocytes with those without this characteristic. Materials and methods: We reviewed all the original histological sections to assess pathological features, and to select a representative area for tissue microarrays and immunohistochemical study. Estrogen and progesterone receptors, HER2 and Ki-67 were evaluated in whole histological sections. The following markers were analyzed in tissue microarrays sections: androgen receptor, cytokeratin 5/6, cytokeratin 14, epidermal growth factor receptor (EGFR), vimentin, p16, claudin-3, -4, and -7, p63, and aldehyde dehydrogenase isoform 1 (ALDH1). Lymphocyte-predominant breast cancer (LPBC) was defined by the presence of more than 50% of lymphocytes in the intratumoral stroma. Results: Twenty-six (22.4%) patients present tumors classified as LPBC and 90 (77.6%) as non-LPBC. The two groups were similar regarding age of patients, tumor grade and Ki-67 positive cells. LPBC cases presented lower frequency of expression of the basal cytokeratins, EGFR, and basal-like immunoprofile. There was a trend to higher expression of ALDH1 by stromal intratumoral cells. The expression of all other markers were similar in the two groups. Conclusions: Lymphocyte-predominant TNBC in premenopausal patients are mostly of non-basal phenotype.
- AXILLARY LYMPH NODE SONOGRAPHIC FEATURES AND BREAST TUMOR CHARACTERISTICS AS PREDICTORS OF MALIGNANCY: A NOMOGRAM TO PREDICT RISK(2017) TEIXEIRA, Patricia Akissue de Camargo; CHALA, Luciano F.; SHIMIZU, Carlos; FILASSI, Jose R.; MAESAKA, Jonathan Y.; BARROS, Nestor deThe purpose of this study was to build a mathematical model to predict the probability of axillary lymph node metastasis based on the ultrasonographic features of axillary lymph nodes and the tumor characteristics. We included 74 patients (75 axillae) with invasive breast cancer who underwent axillary ultrasonography ipsilateral to the tumor and fine-needle aspiration of one selected lymph node. Lymph node pathology results from sentinel lymph node biopsy or surgical dissection were correlated with lymph node ultrasonographic data and with the cytologic findings of fine-needle aspiration. Our mathematical model of prediction risk of lymph node metastasis included only pre-surgical data from logistic regression analysis: lymph node cortical thickness (p = 0.005), presurgical tumor size (p = 0.030), menopausal status (p = 0.017), histologic type (p = 0.034) and tumor location (p = 0.011). The area under the receiver operating characteristic curve of the model was 0.848, reflecting an excellent discrimination of the model. This nomogram may assist in the choice of the optimal axillary approach. (E-mail: pakissue@gmail.com) (C) 2017 World Federation for Ultrasound in Medicine & Biology.
conferenceObject An uncommon beta catenin gene deletion in a breast desmoid-type fibromatosis(2017) SOARES, I. Cauduro; VASCONCELOS, M. A. Pereira Silva; LIMA, L. G. Cernaglia Aureliano de; BATISTA, R. Pedroso; AGUIAR, F. Nalesso; SHIMIZU, C.; RICCI, M. Desiderio; FILASSI, J. R.bookPart Nódulos mamários(2017) MAESAKA, Jonathan Yugo; FILASSI, José RobertobookPart Carcinoma de Mama: Fatores de Risco para o Câncer de Mama(2017) RICCI, Marcos Desiderio; MOTA, Bruna Salani; FILASSI, José Roberto- Post-operative Irradiation after Nipple-Sparing or Skin-Sparing Mastectomy: An International Survey(2017) MARTA, G. N.; POORTMANS, P.; AUDISIO, R. A.; FREITAS JUNIOR, R.; BARROS, A. C. De; FILASSI, J. R.; DESNYDER, S. M.; METERISSIAN, S.; BUCHHOLZ, T. A.; HIJAL, T.
- Multidisciplinary international survey of post-operative radiation therapy practices after nipple-sparing or skin-sparing mastectomy(2017) MARTA, Gustavo Nader; POORTMANS, Philip; BARROS, Alfredo C. de; FILASSI, Jose Roberto; FREITAS JUNIOR, Ruffo; AUDISIO, Riccardo A.; MANO, Max Senna; METERISSIAN, Sarkis; DESNYDER, Sarah M.; BUCHHOLZ, Thomas A.; HIJAL, TarekPurpose/Objective(s): Skin sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM) have entered routine surgical practice for breast cancer, though their oncologic safety has not been established in randomized controlled trials. The aim of this study was to evaluate and compare radiation oncologists' and breast surgeons' opinions concerning the indications of post-operative radiation therapy (PORT) after SSM and NSM. Materials/Methods: Radiation oncologists and breast surgeons from North America, South America and Europe were invited to contribute in this study. A 22-question survey was used to evaluate their opinions. Results: A total of 550 physicians (298 radiation oncologists and 252 breast surgeons) answered the survey. The majority of responders affirmed that PORT should be performed in early-stage (stages I and II) breast cancer for patients who present with risk factors for relapse after SSM and NSM. They considered age, lymph node involvement, tumor size, extracapsular extension, involved surgical margins, lymphovascular invasion, triple negative receptor status and multicentric presentation as major risk factors. Considering that after SSM and NSM, residual breast tissue can be left behind, the residual tissue considered as acceptable in the context of an oncologic surgery were 1-5 mm for breast surgeons. There is no consensus for the necessity of evaluating residual breast tissue through breast imaging. Conclusion: Although the indications of PORT after SSM and NSM vary among practitioners, standard risk factors for relapse are considered as important by radiation oncologists and breast surgeons.
bookPart Descarga papilar(2017) MAESAKA, Jonathan Yugo; FILASSI, José Roberto- Oncoplastic surgery with omental flap reconstruction: a study of 200 cases(2017) MUNHOZ, Alexandre Mendonca; GEMPERLI, Rolf; FILASSI, Jose Roberto